pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BIO International Convention 2026, the most common co-covered peer. Feng Ren appears in 1 tracked Biotech story from June 23, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Feng Ren
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BIO International Convention 2026, the most common co-covered peer. Feng Ren appears in 1 tracked Biotech story from June 23, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Feng Ren. Shared-story counts are live from our verified record — not editorial picks.
In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.
Feng Ren is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
